Novavax, Inc. (NVAX)

The Food and Drug Administration signed off on Novavax's updated Covid booster late Tuesday, and NVAX stock surged just before the close.

Novavax Inc.'s NVAX, +11.57% new COVID shot got a green light from the U.S. Food and Drug Administration Tuesday.

Shares were up more than 10% on the news, which came more than three weeks after vaccines from Moderna and Pfizer.

The U.S. Food and Drug Administration on Tuesday authorized an updated version of Novavax's protein-based COVID-19 vaccine for emergency use in individuals aged 12 years and older, the health regulato...

Health officials see Novavax's protein-based vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna.

As a CNBC report recently pointed out, some publicly traded enterprises are standing out but for the wrong reasons. Feeling the pressure from the specter of an extended period of heightened borrowing ...

European Medicines Agency director Emer Cooke said on Thursday the agency expects to make a decision on Novavax's updated COVID vaccine in October.

Moderna and Novavax both are focused on the coronavirus vaccine market of the future. The two companies each are developing vaccine candidates to prevent coronavirus and flu.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

BA.2.86 is a new COVID variant health officials have been eyeing lately. But recent reports suggest that it may not be all that concerning.